Statin-Associated Autoimmune Myopathy and Inflammatory Myopathies

Diagnosis

Initial evaluation of a patient with muscle weakness should include assessing the distribution, symmetry, and progression of muscle weakness, as well as associated symptoms, according to the American College of Rheumatology 1, 2

The following tests are suggested for diagnostic evaluation:

Test	Description
Muscle enzymes	CPK, LDH, AST
Complete blood count	CBC
Comprehensive metabolic panel	CMP
Inflammatory markers	ESR, CRP
Thyroid function tests	TSH, free T4
25-OH vitamin D levels	Vitamin D
Autoantibody testing	ANA, myositis-specific antibodies

3, 1, 2

Muscle biopsy is the gold standard for diagnosis of many muscle diseases, revealing specific histopathological patterns, including inflammatory infiltrates, dystrophic changes, and specific structural abnormalities, as recommended by the American Heart Association and the American College of Physicians 2, 4

Steroid myopathy and active inflammatory myopathy can be distinguished based on the following parameters:

Parameter	Steroid Myopathy	Active Inflammatory Myopathy
Onset	Insidious	May be acute or subacute
Pain	Usually absent	Often present
Muscle enzymes	Normal or minimally elevated	Significantly elevated
Urinary creatine	Increased	Variable
Response to steroids	Worsens with continued high-dose therapy	Improves with therapy

The American College of Oncology recommends corticosteroids (e.g., Prednisone 0.5-1 mg/kg/day) as the initial treatment for myositis, with analgesics (e.g., Acetaminophen or NSAIDs) for pain management 6
First-line treatment for muscle diseases includes methotrexate, with alternatives such as azathioprine and mycophenolate mofetil, as recommended by the American College of Rheumatology and the Mayo Clinic guidelines 3, 1, 2
For inadequate response to steroids after 4-6 weeks, consider adding or switching immunosuppressants, IVIG therapy, Rituximab, or TNF-α or IL-6 antagonists, as recommended by the American College of Oncology 7, 6
Mycophenolate mofetil (MMF) is particularly useful for both muscle and skin disease, including calcinosis, according to the European League Against Rheumatism 1
Intravenous immunoglobulin (IVIG) is especially helpful when skin features are prominent, as recommended by the European League Against Rheumatism 1
Rituximab can be considered for refractory disease and may take up to 26 weeks to work, according to the European League Against Rheumatism 1
Cyclophosphamide can be considered for severe disease with major organ involvement or extensive ulcerative skin disease, as suggested by the European League Against Rheumatism 1 and the American College of Rheumatology 8
JAK inhibitors can be considered for IIM-ILD progression despite first treatment, according to the American College of Rheumatology 8

For mild to moderate pain, the American Heart Association recommends NSAIDs (e.g., naproxen) if no contraindications 9
Acetaminophen can be used as an alternative for mild to moderate pain, as suggested by the American Society of Clinical Oncology 3
For severe pain/spasms, IV methylprednisolone (1 g/day for 3 days) can be used for severe cases, according to the American Medical Association 2
Symptomatic management of pain with acetaminophen or NSAIDs is recommended if there are no contraindications, as recommended by the American College of Rheumatology 3

Include a physiotherapist and specialist nurse as part of the multidisciplinary team, as recommended by the European League Against Rheumatism 1
Regular assessment of muscle strength, serial creatine kinase (CK) measurements, functional status improvement, and ability to taper corticosteroids are crucial monitoring parameters, as recommended by the Mayo Clinic guidelines and the American College of Rheumatology 2, 3, 1
Annual assessment of disease damage using validated indices, such as the Myositis Damage Index, is recommended to evaluate the effectiveness of treatment, as recommended by the American College of Rheumatology and the European League Against Rheumatism 3, 1
Target CK levels should be in the low-normal range, as recommended by the Mayo Clinic guidelines and the American College of Rheumatology 2, 3

The American Heart Association warns of cardiac complications, including progressive atrioventricular or intraventricular conduction defects and tachyarrhythmias, in certain muscle diseases 4
Respiratory complications can be life-threatening in some muscle diseases, as described by the American Heart Association 4
Common side effects of IVIG therapy include headache, fever, nausea, myalgia, and infusion-related reactions, while more serious but rare complications include thromboembolic events, aseptic meningitis, renal dysfunction, and hemolytic anemia, as described by the Mayo Clinic guidelines 2
The Mayo Clinic Proceedings recommends monitoring for dysphagia and considering interventions to prevent aspiration pneumonia in patients with IBM 2
Corticosteroids are not effective for IBM, unlike other inflammatory myopathies, as stated by the Mayo Clinic Proceedings 2
The American College of Cardiology recommends immediate cessation of statin therapy if statin-associated autoimmune myopathy is suspected, as this condition requires statin cessation and aggressive immunotherapy directed at the autoimmune process 10